Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
Just over 140 years ago, the world’s first industrial-sized research and development laboratory opened. As someone who’s devoted his working life to finding new research and development (R&D) breakthroughs, I’m envious of the explosion of activity that made the lab’s owner, Thomas Edison, one of history’s most remarkable inventors. But it’s his process of innovation that inspires me, as much as his life-changing creations. 27 November 2018
Biotechnology
Greg MacMichael, the former global head of cell and gene therapy technical development and manufacturing at Swiss pharma giant Novartis, is one of five new recruits to join Axovant Sciences. 26 November 2018
Pharmaceutical
Forty-five years ago, Japan eliminated strict limits on the percentage ownership permitted for foreign pharma companies in Japan. The path was cleared for 100% ownership of a Japan entity, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. 26 November 2018
Pharmaceutical
In the USA alone, more than 10% of adults or adolescents take antidepressants, and fully two-thirds of these people do not respond to first-line treatment, normally a selective serotonin reuptake inhibitor (SSRI) such as Zoloft (sertraline) or Celexa (citalopram). 26 November 2018
Biotechnology
In recent decades, the pharmaceutical industry has developed next-generation treatments for cystic fibrosis (CF) that have a real impact on patients’ lives and extend life expectancy considerably. 23 November 2018
Pharmaceutical
The success of any pre-clinical research program relies on selecting the right animal for a study, writes Emmanuel Gomas, European services manager at Envigo, in an expert view piece. 21 November 2018
Biotechnology
With current Gilead Sciences chief executive John Milligan standing down at the end of the year, the announcement on his successor is one of the most eagerly-awaited in biopharma at present. 21 November 2018
Biotechnology
In an Expert View column, Stephen Bennett (pictured) and Mary Foord-Weston, from UK-based law firm Hogan Lovells, consider the questions that new oncology treatments raise around the current intellectual property (IP) system. 16 November 2018
Biotechnology
Novo Nordisk’s (NOV: N) decision to spend up to $800 million buying the synthetic glucose specialist Ziylo has thrown a spotlight on Unit DX, a biotech incubator based in Bristol, UK. 15 November 2018
Biosimilars
Jean-Yves Brault, UK country manager for Mylan, considers the much-needed copies of biologics that are now coming to the fore. 12 November 2018
Pharmaceutical
Big things are happening in oncology at the moment. Considering all stages of clinical development, there are thought to be up to 8,000 anticancer candidates being tested by drugmakers globally. 12 November 2018
Biotechnology
As far as PARP inhibitors are concerned, AstraZeneca stole the show at the annual congress of ESMO this month, with the SOLO-1 trial of Lynparza (olaparib) showing striking data in the first-line maintenance setting for ovarian cancer patients. 9 November 2018
Biotechnology
UK-headquartered commercial-stage biotech firm Orchard Therapeutics today announced two additions to its global commercial leadership team, appointing Robin Kenselaar as senior vice president and general manager, EMEA commercial operations, and Brad Mathis as vice president, US commercial operations. 8 November 2018
Biotechnology
Dutch biopharma Kiadis Pharma has appointed three new senior team members to empower its transition into the commercial stage. 8 November 2018
Pharmaceutical
Drug companies, which have learned to live with advertisements calling out a litany of possible side effects for their drugs, may want to take a couple of aspirin. That’s because the Department of Health and Human Services recently announced a new proposed rule by the Centers for Medicare and Medicaid Services that would require them to disclose the list price — more precisely, the wholesale acquisition cost — of medications they sell in direct-to-consumer television ads. 7 November 2018
Pharmaceutical
Novartis has invested over $150 million in the development of its Russian plant in St Petersburg, and is considering further investments in the near future, according to recent statements by Vadim Vlasov, president of the Swiss pharma giant’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 5 November 2018
Pharmaceutical
In an Expert View column, Helen Westropp, managing partner of branding agency Coley Porter Bell, describes how tens of millions of dollars are wasted in M&A deals every year when acquirers fail to understand the value in the brand and culture of the business they are buying. This is particularly the case in pharma and biotech businesses. 5 November 2018
Generics
Russia maybe faced with a shortage of certain pain management drugs this year, due to the end of supplies of active ingredients for their production from the UK, according to recent statements by the director of the Moscow Endocrine Plant, Mikhail Fonarev, reports The Pharma Letter’s local correspondent. 5 November 2018
Pharmaceutical
When Per Falk, Ferring’s chief science officer, assumes the additional responsibility of becoming president of the executive committee on January 1 next year, he will be the envy of many big pharma leaders. 5 November 2018
article
Welcome again to The Pharma Letter’s new column, RARE: Illuminating Orphan Diseases.
November 1 was Acromegaly Awareness Day, a day to heighten public understanding of a rare hormonal disorder that affects sixty out of every one million people.1 We take a deep dive into the current treatment options, treatment gaps, and future directions pharma can take to improve treatment for acromegaly. 5 November 2018
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze